We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+0.34%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.02B
AUM Growth
-$106M
Cap. Flow
-$45.5M
Cap. Flow %
-2.25%
Top 10 Hldgs %
46.17%
Holding
96
New
10
Increased
23
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.5M
2
AMGN icon
Amgen
AMGN
+$23.8M
3
SYK icon
Stryker
SYK
+$20.1M
4
JNJ icon
Johnson & Johnson
JNJ
+$19.2M
5
BSX icon
Boston Scientific
BSX
+$12.8M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$41.2M
2
ZBH icon
Zimmer Biomet
ZBH
+$39.6M
3
AVTR icon
Avantor
AVTR
+$34.3M
4
VEEV icon
Veeva Systems
VEEV
+$27.5M
5
WST icon
West Pharmaceutical
WST
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHC icon
26
Acadia Healthcare
ACHC
$2.55B
$28.4M 1.4%
420,164
+152,430
+57% +$10.6M
BSX icon
27
Boston Scientific
BSX
$68.4B
$26.8M 1.33%
348,107
+175,321
+101% +$12.8M
UNH icon
28
CALL
UnitedHealth
UNH
$382B
$26.7M 1.32%
+52,400
New +$25.7M
DXCM icon
29
DexCom
DXCM
$29B
$26.2M 1.3%
231,007
+75,129
+48% +$9.5M
AMGN icon
30
Amgen
AMGN
$209B
$25.3M 1.25%
+81,034
New +$23.8M
IQV icon
31
IQVIA
IQV
$40.7B
$23.7M 1.17%
111,854
– –
MOH icon
32
Molina Healthcare
MOH
$10.4B
$20.8M 1.03%
70,088
– –
JNJ icon
33
Johnson & Johnson
JNJ
$640B
$18.8M 0.93%
+128,825
New +$19.2M
PRAX icon
34
Praxis Precision Medicines
PRAX
$8.11B
$18.7M 0.93%
453,146
-24,459
-5% -$1.16M
ACLX
35
DELISTED
Arcellx
ACLX
$17.2M 0.85%
311,980
+8,770
+3% +$477K
INSM icon
36
Insmed
INSM
$22.4B
$16.2M 0.8%
+241,315
New +$9.36M
EPIX
37
DELISTED
ESSA Pharma
EPIX
$15.6M 0.77%
2,965,442
-14,978
-0.5% -$95.2K
IWM icon
38
PUT
iShares Russell 2000 ETF
IWM
$79.1B
$14.3M 0.71%
+70,700
New +$14.3M
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.64B
$13.9M 0.69%
88,216
+76,925
+681% +$9.88M
CELC icon
40
Celcuity
CELC
$4.06B
$13.7M 0.68%
837,002
+340,000
+68% +$5.69M
OSCR icon
41
Oscar Health
OSCR
$9.22B
$13.6M 0.67%
860,821
– –
IMVT icon
42
Immunovant
IMVT
$7.93B
$12.5M 0.62%
472,540
– –
ITCI
43
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.7M 0.58%
170,400
+71,521
+72% +$4.96M
ERAS icon
44
Erasca
ERAS
$6.15B
$11M 0.55%
4,671,774
+2,136,672
+84% +$4.61M
ADAP
45
DELISTED
Adaptimmune Therapeutics
ADAP
$10.3M 0.51%
10,520,231
+97,096
+0.9% +$107K
MDGL icon
46
Madrigal Pharmaceuticals
MDGL
$12.6B
$8.4M 0.42%
29,973
– –
SNDX icon
47
Syndax Pharmaceuticals
SNDX
$1.7B
$7.95M 0.39%
387,357
-271,337
-41% -$5.68M
HOWL icon
48
Werewolf Therapeutics
HOWL
$22.4M
$7.91M 0.39%
3,241,074
+234,340
+8% +$1.13M
CRBU icon
49
Caribou Biosciences
CRBU
$146M
$6.7M 0.33%
4,083,372
-2,399,898
-37% -$7.67M
CMPS
50
Compass Pathways
CMPS
$1.47B
$6.58M 0.33%
1,089,592
– –
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
AC
AWM Capital Phoenix, Arizona $1.1B AUM 15.03% 1-Year Est. Return

PFM Health Sciences's Q2 2024 Portfolio in Review

As of Q2 2024, PFM Health Sciences held 96 positions worth $2.02B, down 5% from $2.13B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences's Q2 2024 filing shows 10 new, 23 increased, 12 reduced and 18 closed positions. Its largest new stake was Amgen: 81,034 shares worth $25.3M. The largest sale was Legend Biotech, an estimated $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

  • PFM Health Sciences's largest Q2 2024 buy was Amgen: 81,034 shares worth $25.3M.
  • PFM Health Sciences added most to UnitedHealth in Q2 2024, an estimated $24.5M increase.
  • PFM Health Sciences's biggest Q2 2024 reduction was Becton Dickinson, cutting an estimated $9.46M.
  • PFM Health Sciences fully exited Legend Biotech in Q2 2024, selling an estimated $41.2M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $2.02B portfolio in Q2 2024.
  • PFM Health Sciences opened 10 new positions and closed 18 in Q2 2024.
  • PFM Health Sciences's portfolio value fell 5% quarter-over-quarter to $2.02B.

Based on PFM Health Sciences's 13F filing for Q2 2024, filed 14 Aug 2024.